Plain-English translation of NCT06083103 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This trial is testing whether a newer imaging scan called PET/MRI is better than the standard PET/CT scan at finding cancer that may have spread to lymph nodes in women with advanced cervical cancer. Both scans use a safe radioactive tracer to help doctors see where cancer cells are in your body. The study will compare how well each scan detects cancer spread so doctors can choose the most accurate tool for patient care.
Doctors need the most accurate imaging possible to find all the cancer in your body before treatment begins, because knowing the full extent of the disease helps them plan the best treatment for you. This trial will help doctors understand if the newer imaging technology can find cancer spread more reliably than the current standard scan.
You likely qualify if…
You likely don't qualify if…
You will come in for one visit where you receive a radioactive tracer injection, then you'll have two imaging scans back-to-back: a standard PET/CT scan (which you were already going to have as part of your normal care) followed immediately by a PET/MRI scan. Both scans use the same tracer dose, so you're not exposed to extra radiation. The whole visit takes a few hours, and after that your participation is complete — the doctors will use the scan results to help plan your cancer treatment.
AI-generated summary from trial data · Aug 8, 2026 · Not medical advice
France
Sponsor
Centre Paul Strauss
Enrollment target
~50 participants
Started
October 2023
Primary completion
September 2026
This trial's estimated completion date has passed — the record may not be fully up to date.
Age range
18 Years and older
Sex
Female only
Last updated on clinicaltrials.gov in February 2026.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Claire VIT
Institut de cancérologie Strasbourg Europe
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.